The prevalence of and mortality due to lung cancer have been steadily increasing worldwide. Based on differences in treatment strategies, lung cancer can be classified as non-smallcell lung cancer (NSCLC) and small-cell lung cancer (SCLC). NSCLC mainly consists of adenocarcinoma and squamous cell carcinoma, comprising about 80% of the total lung cancer cases. The treatment strategy for NSCLC is...

To study and analyze the effect of bevacizumab-related hypertension on prognosis patients with colorectal cancer non-small cell lung cancer. The randomly selected 100 who received therapy in our hospital from October 2019 to 2021. Among them, adopted intervention for bevacizumab combined cytotoxic drug chemotherapy standard chemotherapy. Bevacizumab treatment has better therapeutic than patient...

There are no data available combining transbronchial needle aspiration (TBNA) of mediastinal lymph nodes and positron emission tomography (PET) in the staging of nonsmall cell lung cancer (NSCLC). The aim of the current study was to determine if these two methods can enhance the negative predictive value of the individual modality alone, for a specific lymph node station, and if this integrated...

ceptor tyrosine kinase expressed in the majority of nonsmall-cell lung cancers (NSCLC) (Dazzi et al. 1989; Kaseda et al. 1989). The efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs) in preclinical tumor models, together with their favorable toxicity profiles, led to their clinical development in NSCLC and other solid tumors (Higgins et al. 2004). Erlotinib and gefitinib are smallmolecule ...

High blood tumor mutational burden (bTMB) was significantly associated with progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients receiving atezolizumab. However, it failed to predict overall (OS). We hypothesized that ctDNA mass-adjusted bTMB (abTMB) might benefits NSCLC immune checkpoint inhibitors (ICIs) treatment.

Purpose: The discovery of EGFR mutations renewed interest in lung cancer translational research since EGFR-dependent pathway plays an important role in the development and progression of human epithelial cancers, including nonsmall cell lung cancer (NSCLC). The present meta-analysis was performed to review the recent advances with the selective oral EGFR-TK inhibitor gefitinib among EGFR mutati...

Minimally invasive surgery (MIS) is gradually becoming the standard of care for surgical treatment nonsmall cell lung cancer (NSCLC). Compared with multiple incision approach, including conventional multiportal video-assisted thoracoscopic (mVATS) and robotic-assisted (mRATS), uniportal (uVATS) offers a range potential benefits such as straight target view from sagittal plane, better exposure, ...

Objective(s): To investigate the role of miR-22 in the efficacy of combined icotinib (BPI-2009H) and pemetrexed (LY-231514) on tumor growth and apoptosis in rats with non-small cell lung cancer (NSCLC).Materials and Methods: Rats were injected with HCC827 cells, which were transfected with anti-miR-22, followed by the treatment of BPI-20...

Fragile histidine triad (FHIT) is a tumour suppressor gene, which is altered in a variety of epithelial tumours, including lung cancer. Biochemical and functional pathways of its tumourigenicity are not yet understood. Its role in tumour proliferation is particularly controversial. The purpose of this study was to correlate the expression of FHIT protein in nonsmall cell lung cancer (NSCLC) wit...

Nonsmall cell lung cancer (NSCLC) is one of the leading causes of death worldwide. TNF-related apoptosis-inducing ligand (TRAIL) has been shown to induce apoptosis in malignant cells without inducing significant toxicity in normal cells. However, several carcinomas, including lung cancer, remain resistant to TRAIL. MicroRNAs (miRNAs) are small noncoding RNAs of ∼ 24 nt that block mRNA translati...